

**Table S2.** Exposure to study medication assigned by trimester

| <b>Trimester</b>                                                                    | <b>Study cohort<br/>n=219</b> | <b>NSAID<br/>n=183</b> | <b>NSAID/PCM<br/>n=20</b> | <b>PCM<br/>n=16</b> |
|-------------------------------------------------------------------------------------|-------------------------------|------------------------|---------------------------|---------------------|
|                                                                                     | n (%)                         | n (%)                  | n (%)                     | n (%)               |
| <b>2<sup>nd</sup> trimester only</b>                                                | 41 (18.7%)                    | 32 (17.5%)             | 5 (25.0%)                 | 4 (25.0%)           |
| <b>3<sup>rd</sup> trimester</b>                                                     | 126 (57.5%)                   | 110 (60.1%)            | 9 (45.0%)                 | 7 (43.75%)          |
| <b>2<sup>nd</sup> and 3<sup>rd</sup> trimester</b>                                  | 37 (16.9%)                    | 30 (16.4%)             | 4 (20.0%)                 | 3 (18.75%)          |
| <b>Not further assignable to 2<sup>nd</sup><br/>and/or 3<sup>rd</sup> trimester</b> | 15 (6.6%)                     | 11 (6.0%)              | 2 (10.0%)                 | 2 (12.5%)           |

n, number of cases; NSAID, non-steroidal anti-inflammatory drugs; PCM, paracetamol.